The liver metastasis was always regarded as an impressive poor prognostic factor in solid tumors, and the patients had a short survival for several months. http://www.selleckchem.com/products/tofacitinib-cp-690550.html The patients with a resectable liver metastatic GIST had to undergo Inhibitors,Modulators,Libraries a second line localized resection or so called cytoreductive surgery. Imatinib mesylate was proved to have an impressive therapeutic effect on the patients with an advanced GIST. A good 2 year sur vival rate of 95. 2% was found in the patients who had only a liver metastatic GIST after the prior radical resection combined with the treatment Inhibitors,Modulators,Libraries of imatinib mesylate. However, the relationship between the liver metastasis and the outcome of the imatinib mesylate treatment has rarely been studied. So, the present study was focused on whether the liver metastasis would influence the survival of the patients who were treated with imatinib mesylate.

Although the results from our previous study answers the above question Inhibitors,Modulators,Libraries to some extent. The present study fur ther proved that imatinib mesylate was able to prolong the survival time of the patients who had suffered from recurrent GIST after the radical surgery. Our median fol low up for 39. 5 months revealed that 21 patients were still alive, with a 3 year survival rate of 66. 7% and a median overall survival of 48 months. Oral imatinib mesylate, instead of another palli ative surgery, was the reasonable choice for the patients who had recurrent GISTs that can not be radically removed. Inhibitors,Modulators,Libraries The clinical data from the patients in the LG, the AG and the ALG group were comparable.

The analy sis showed that the patients in the three groups had a similar tumor response rate, TTP and OS. In the LG group, 7 of the 10 patients who had only liver metastatic GIST were still alive when the clinical data were evalu ated. Those patients achieved the highest 3 year survival rate of 80% in the Inhibitors,Modulators,Libraries current study. Survival was not signifi cantly affected by liver metastases when imatinib mesy late was warranted. Edema and anemia, although mild and well tolerated, were the commonest adverse effects observed during this long term imatinib mesylate treatment. No treatment related death occurred. Tumors resistance to imatinib mesylate is still a major problem. An increase of the imatinib mesylate dose to 600 mg per day or a maximal dose of 800 mg per day is useful but its effectiveness only lasts for a short time.

A change to another targeting agent, such as sunitinib, could improve the outcome. In our study, for the eco nomic reason, only 12 of the 26 patients selleck chem Idelalisib who had tumor progression used an increased dose of imatinib mesylate, only 3 patients were given sunitinib. The tumor control rate achieved by the second line ther apy was 23. 1% in our study. The median survival time was 5 months after the failure of the imatinib mesylate treatment of 400 mg per day.